HSN-002066 / Beijing Pharscin InnoBio - LARVOL DELTA

Discovery of a novel and highly selective PARP7 inhibitor for cancer immunotherapy (AACR 2024) - "Notably, HSN002066 and RBN-2397, the only PARP7 inhibitor currently in Ph 1/2 clinical development, displayed differentiated antiproliferative activities in cell line NCI-H1373 (IC50 are 387.8 nM and 15.2 nM, respectively). However, HSN002066 revealed remarkable antitumor effects as monotherapy (TGI 77% at 100 mg/kg) or combination with PD-1 antibody in CT-26 allograft model.The structure of HSN002066 was not presented and will not be disclosed at the time of presentation at AACR meeting."

Oncology • TIPARP